{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:56:07Z","timestamp":1789210567615,"version":"build-2803163510"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The mitogen-activated protein kinase (MAPK) signaling pathways play essential roles in cell proliferation and differentiation. Recent studies also show the activation of MAPK signaling pathways in tumorigenesis, metastasis, and angiogenesis of multiple human malignancies, including renal cell carcinoma (RCC). To assess the role of this pathway in regulating the proliferation and survival of RCC cells, we first examined the expression of MAPK kinase (MKK) and MAPK in clear cell RCC and confirmed the overexpression of MKK1 and extracellular signal-regulated kinase 2 (ERK2) in these tumors. We then tested the effects of pharmacologic inhibition of MKK on human RCC cell lines, both in vitro and in vivo, using anthrax lethal toxin (LeTx), which cleaves and inactivates several MKKs. Western blotting showed that the phosphorylation levels of ERK, c-Jun-NH2 kinase, and p38 MAPK decreased after 72 h of LeTx treatment. Exposure to LeTx for 72 h reduced cell proliferation by 20% without significant effects on cell cycle distribution and apoptosis. Anchorage-independent growth of RCC cells was dramatically inhibited by LeTx. In vivo studies showed that tumor growth of RCC xenografts could be suppressed by LeTx. Extensive necrosis and decreased tumor neovascularization were observed after LeTx treatment. LeTx also showed direct inhibition of proliferation of endothelial cells in vitro. Our results suggest that suppression of one or more MAPK signaling pathways may inhibit RCC growth through the disruption of tumor vasculature. [Cancer Res 2008;68(1):81\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5311","type":"journal-article","created":{"date-parts":[[2008,1,2]],"date-time":"2008-01-02T21:02:33Z","timestamp":1199307753000},"page":"81-88","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":173,"title":["Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis\n                    <i>In vivo<\/i>"],"prefix":"10.1158","volume":"68","author":[{"given":"Dan","family":"Huang","sequence":"first","affiliation":[{"name":"1Laboratory of Cancer Genetics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ding","sequence":"additional","affiliation":[{"name":"2Laboratory of Cancer and Developmental Cell Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Mei","family":"Luo","sequence":"additional","affiliation":[{"name":"1Laboratory of Cancer Genetics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bender","sequence":"additional","affiliation":[{"name":"1Laboratory of Cancer Genetics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Nan","family":"Qian","sequence":"additional","affiliation":[{"name":"1Laboratory of Cancer Genetics,"},{"name":"4Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kort","sequence":"additional","affiliation":[{"name":"1Laboratory of Cancer Genetics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Fa","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Laboratory of Cancer Genetics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"VandenBeldt","sequence":"additional","affiliation":[{"name":"3Laboratory of Analytical, Cellular, and Molecular Microscopy, Laboratory of Microarray Technology, Van Andel Research Institute, Grand Rapids, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Duesbery","sequence":"additional","affiliation":[{"name":"2Laboratory of Cancer and Developmental Cell Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Resau","sequence":"additional","affiliation":[{"name":"3Laboratory of Analytical, Cellular, and Molecular Microscopy, Laboratory of Microarray Technology, Van Andel Research Institute, Grand Rapids, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin Tean","family":"Teh","sequence":"additional","affiliation":[{"name":"1Laboratory of Cancer Genetics,"},{"name":"5NCCS-VARI Translational Research Laboratory, National Cancer Center, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,1,2]]},"reference":[{"key":"2022061623201863800_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin\u20082006; 56: 106\u201330.","DOI":"10.3322\/canjclin.56.2.106"},{"key":"2022061623201863800_B2","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med\u20081996; 335: 865\u201375.","DOI":"10.1056\/NEJM199609193351207"},{"key":"2022061623201863800_B3","doi-asserted-by":"crossref","unstructured":"Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res\u20082007; 13: 1367\u201373.","DOI":"10.1158\/1078-0432.CCR-06-2328"},{"key":"2022061623201863800_B4","doi-asserted-by":"crossref","unstructured":"Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist\u20082007; 12: 107\u201313.","DOI":"10.1634\/theoncologist.12-1-107"},{"key":"2022061623201863800_B5","doi-asserted-by":"crossref","unstructured":"Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res\u20082006; 12: 7271\u20138.","DOI":"10.1158\/1078-0432.CCR-06-1249"},{"key":"2022061623201863800_B6","doi-asserted-by":"crossref","unstructured":"Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature\u20082001; 410: 37\u201340.","DOI":"10.1038\/35065000"},{"key":"2022061623201863800_B7","doi-asserted-by":"crossref","unstructured":"Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science\u20082002; 298: 1911\u20132.","DOI":"10.1126\/science.1072682"},{"key":"2022061623201863800_B8","doi-asserted-by":"crossref","unstructured":"Dunn KL, Espino PS, Drobic B, He S, Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol\u20082005; 83: 1\u201314.","DOI":"10.1139\/o04-121"},{"key":"2022061623201863800_B9","unstructured":"Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature\u20082002; 417: 949\u201354."},{"key":"2022061623201863800_B10","doi-asserted-by":"crossref","unstructured":"Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A\u20081998; 95: 14417\u201322.","DOI":"10.1073\/pnas.95.24.14417"},{"key":"2022061623201863800_B11","doi-asserted-by":"crossref","unstructured":"Webb CP, Taylor GA, Jeffers M, et al. Evidence for a role of Met-HGF\/SF during Ras-mediated tumorigenesis\/metastasis. Oncogene\u20081998; 17: 2019\u201325.","DOI":"10.1038\/sj.onc.1202135"},{"key":"2022061623201863800_B12","doi-asserted-by":"crossref","unstructured":"Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol\u20082001; 21: 5958\u201369.","DOI":"10.1128\/MCB.21.17.5958-5969.2001"},{"key":"2022061623201863800_B13","doi-asserted-by":"crossref","unstructured":"Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest\u20081997; 99: 1478\u201383.","DOI":"10.1172\/JCI119309"},{"key":"2022061623201863800_B14","doi-asserted-by":"crossref","unstructured":"Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK\/MAP kinase in glial neoplasms. Am J Pathol\u20081998; 153: 1411\u201323.","DOI":"10.1016\/S0002-9440(10)65728-8"},{"key":"2022061623201863800_B15","doi-asserted-by":"crossref","unstructured":"Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-\/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene\u20081999; 18: 813\u201322.","DOI":"10.1038\/sj.onc.1202367"},{"key":"2022061623201863800_B16","unstructured":"Salh B, Marotta A, Matthewson C, et al. Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res\u20081999; 19: 731\u201340."},{"key":"2022061623201863800_B17","doi-asserted-by":"crossref","unstructured":"Giroux S, Tremblay M, Bernard D, et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol\u20081999; 9: 369\u201372.","DOI":"10.1016\/S0960-9822(99)80164-X"},{"key":"2022061623201863800_B18","doi-asserted-by":"crossref","unstructured":"Berra E, Milanini J, Richard DE, et al. Signaling angiogenesis via p42\/p44 MAP kinase and hypoxia. Biochem Pharmacol\u20082000; 60: 1171\u20138.","DOI":"10.1016\/S0006-2952(00)00423-8"},{"key":"2022061623201863800_B19","unstructured":"Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte growth factor\/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res\u20082001; 61: 5911\u20138."},{"key":"2022061623201863800_B20","doi-asserted-by":"crossref","unstructured":"Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin \u03b1v\u03b23 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol\u20081998; 140: 1255\u201363.","DOI":"10.1083\/jcb.140.5.1255"},{"key":"2022061623201863800_B21","doi-asserted-by":"crossref","unstructured":"Depeille P, Young JJ, Boguslawski EA, et al. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral g protein coupled receptor. Clin Cancer Res\u20082007; 13: 5926\u201334.","DOI":"10.1158\/1078-0432.CCR-07-0732"},{"key":"2022061623201863800_B22","unstructured":"Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res\u20081995; 55: 4182\u20137."},{"key":"2022061623201863800_B23","doi-asserted-by":"crossref","unstructured":"Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science\u20081998; 280: 734\u20137.","DOI":"10.1126\/science.280.5364.734"},{"key":"2022061623201863800_B24","doi-asserted-by":"crossref","unstructured":"Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS\/IFN\u03b3-induced release of NO and TNF\u03b1. FEBS Lett\u20081999; 462: 199\u2013204.","DOI":"10.1016\/S0014-5793(99)01502-1"},{"key":"2022061623201863800_B25","doi-asserted-by":"crossref","unstructured":"Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine\/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun\u20081998; 248: 706\u201311.","DOI":"10.1006\/bbrc.1998.9040"},{"key":"2022061623201863800_B26","doi-asserted-by":"crossref","unstructured":"Liang X, Young JJ, Boone SA, Waugh DS, Duesbery NS. Involvement of domain II in toxicity of anthrax lethal factor. J Biol Chem\u20082004; 279: 52473\u20138.","DOI":"10.1074\/jbc.M409105200"},{"key":"2022061623201863800_B27","doi-asserted-by":"crossref","unstructured":"Duesbery NS, Resau J, Webb CP, et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A\u20082001; 98: 4089\u201394.","DOI":"10.1073\/pnas.061031898"},{"key":"2022061623201863800_B28","doi-asserted-by":"crossref","unstructured":"Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A\u20082002; 99: 3052\u20137.","DOI":"10.1073\/pnas.052707699"},{"key":"2022061623201863800_B29","doi-asserted-by":"crossref","unstructured":"Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein\/extracellular signal-regulated kinase kinase 1\/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther\u20082005; 4: 1303\u201310.","DOI":"10.1158\/1535-7163.MCT-05-0145"},{"key":"2022061623201863800_B30","doi-asserted-by":"crossref","unstructured":"Abi-Habib RJ, Singh R, Leppla SH, et al. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clin Cancer Res\u20082006; 12: 7437\u201343.","DOI":"10.1158\/1078-0432.CCR-06-2019"},{"key":"2022061623201863800_B31","doi-asserted-by":"crossref","unstructured":"Park S, Leppla SH. Optimized production and purification of Bacillus anthracis lethal factor. Protein Expr Purif\u20082000; 18: 293\u2013302.","DOI":"10.1006\/prep.2000.1208"},{"key":"2022061623201863800_B32","doi-asserted-by":"crossref","unstructured":"Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res\u20082007; 67: 3171\u20136.","DOI":"10.1158\/0008-5472.CAN-06-4571"},{"key":"2022061623201863800_B33","doi-asserted-by":"crossref","unstructured":"Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol\u20082006; 169: 1875\u201385.","DOI":"10.2353\/ajpath.2006.050711"},{"key":"2022061623201863800_B34","doi-asserted-by":"crossref","unstructured":"Nomura T, Huang WC, Zhau HE, et al. \u03b22-Microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res\u20082006; 12: 7294\u2013305.","DOI":"10.1158\/1078-0432.CCR-06-2060"},{"key":"2022061623201863800_B35","doi-asserted-by":"crossref","unstructured":"Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. Curr Opin Cell Biol\u20081999; 11: 737\u201344.","DOI":"10.1016\/S0955-0674(99)00045-9"},{"key":"2022061623201863800_B36","doi-asserted-by":"crossref","unstructured":"Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol\u20081997; 9: 701\u20136.","DOI":"10.1016\/S0955-0674(97)80124-X"},{"key":"2022061623201863800_B37","unstructured":"Gold R, Schmied M, Giegerich G, et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest\u20081994; 71: 219\u201325."},{"key":"2022061623201863800_B38","doi-asserted-by":"crossref","unstructured":"Collins RJ, Harmon BV, Gobe GC, Kerr JF. Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis. Int J Radiat Biol\u20081992; 61: 451\u20133.","DOI":"10.1080\/09553009214551201"},{"key":"2022061623201863800_B39","doi-asserted-by":"crossref","unstructured":"Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene\u20081997; 15: 2169\u201377.","DOI":"10.1038\/sj.onc.1201380"},{"key":"2022061623201863800_B40","doi-asserted-by":"crossref","unstructured":"Clauss M, Sunderkotter C, Sveinbjornsson B, et al. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood\u20082001; 97: 1321\u20139.","DOI":"10.1182\/blood.V97.5.1321"},{"key":"2022061623201863800_B41","unstructured":"Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1\u03b1. Cancer Res\u20082000; 60: 4873\u201380."},{"key":"2022061623201863800_B42","doi-asserted-by":"crossref","unstructured":"Vasilevskaya I, O'Dwyer PJ. Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat\u20082003; 6: 147\u201356.","DOI":"10.1016\/S1368-7646(03)00043-8"},{"key":"2022061623201863800_B43","doi-asserted-by":"crossref","unstructured":"Qi M, Elion EA. MAP kinase pathways. J Cell Sci\u20082005; 118: 3569\u201372.","DOI":"10.1242\/jcs.02470"},{"key":"2022061623201863800_B44","doi-asserted-by":"crossref","unstructured":"Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the map kinase kinases MKK3 and MKK6. J Biol Chem\u20081998; 273: 1741\u20138.","DOI":"10.1074\/jbc.273.3.1741"},{"key":"2022061623201863800_B45","doi-asserted-by":"crossref","unstructured":"Depeille PE, Ding Y, Bromberg-White JL, Duesbery NS. MKK signaling and vascularization. Oncogene\u20082007; 26: 1290\u20136.","DOI":"10.1038\/sj.onc.1210198"},{"key":"2022061623201863800_B46","doi-asserted-by":"crossref","unstructured":"Milanini J, Vinals F, Pouyssegur J, Pages G. p42\/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem\u20081998; 273: 18165\u201372.","DOI":"10.1074\/jbc.273.29.18165"},{"key":"2022061623201863800_B47","unstructured":"Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2\/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol\u20081997; 151: 1523\u201330."},{"key":"2022061623201863800_B48","doi-asserted-by":"crossref","unstructured":"Kirby JE. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect Immun\u20082004; 72: 430\u20139.","DOI":"10.1128\/IAI.72.1.430-439.2004"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/1\/81\/2591051\/81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/1\/81\/2591051\/81.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T22:32:44Z","timestamp":1655418764000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/1\/81\/540537\/Inhibition-of-MAPK-Kinase-Signaling-Pathways"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,1,2]]},"published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5311","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22373402.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373399.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373402","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371102","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371099","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373399","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371105","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371096","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371108","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371096.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371102.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371099.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371108.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371105.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496662.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}